Publications by authors named "Valentina Guarneri"

100Publications

Implications of metabolism-driven myeloid dysfunctions in cancer therapy.

Cell Mol Immunol 2020 Oct 19. Epub 2020 Oct 19.

Department of Pharmaceutical Sciences, University of Eastern Piedmont, A. Avogadro, via Bovio 6, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41423-020-00556-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570408PMC
October 2020

Should triple-positive breast cancer be recognized as a distinct subtype?

Expert Rev Anticancer Ther 2020 Oct 6:1-4. Epub 2020 Oct 6.

Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1829484DOI Listing
October 2020

Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.

Cancer Treat Rev 2020 Aug 24;88:102064. Epub 2020 Jun 24.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102064DOI Listing
August 2020

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.

Oncologist 2020 Jun 18. Epub 2020 Jun 18.

Medical Oncology 2, Istituto Oncologico Veneto (IOV)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0148DOI Listing
June 2020

Cancer and COVID-19: what do we really know?

Lancet 2020 06 29;395(10241):1884-1885. Epub 2020 May 29.

Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, University of Lisbon, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)31240-XDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259910PMC
June 2020

Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.

Cancer Treat Rev 2020 Jul 16;87:102031. Epub 2020 May 16.

Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102031DOI Listing
July 2020

Olaparib for advanced breast cancer.

Future Oncol 2020 Apr 6;16(12):717-732. Epub 2020 Apr 6.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0689DOI Listing
April 2020

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.

Int J Mol Sci 2020 Feb 26;21(5). Epub 2020 Feb 26.

Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21051601DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084664PMC
February 2020

Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.

Cell Stress 2019 Jul 1;3(9):284-294. Epub 2019 Jul 1.

Division of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15698/cst2019.09.197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732213PMC
July 2019

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.

Oncologist 2019 11 23;24(11):e1055-e1069. Epub 2019 Aug 23.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853089PMC
November 2019

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

J Immunother Cancer 2019 03 29;7(1):90. Epub 2019 Mar 29.

Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0548-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439986PMC
March 2019

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.

J Ovarian Res 2019 Jan 28;12(1). Epub 2019 Jan 28.

Department of Health of Woman and Child, Gynecologic Oncology Unit, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-019-0484-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348631PMC
January 2019

Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy.

J Thorac Oncol 2019 01;14(1):e5-e7

Medical Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padua, Italy; Department of Surgery, Oncology, and Gastroenterology, Univeristy of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.08.2033DOI Listing
January 2019

Escalation and de-escalation in HER2 positive early breast cancer.

Curr Opin Oncol 2019 01;31(1):35-42

Department of Surgery, Oncology and Gastroenterology, University of Padova.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000492DOI Listing
January 2019

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?

Crit Rev Oncol Hematol 2018 Aug 24;128:19-29. Epub 2018 May 24.

Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Via Gattamelata 64, 35128 Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.05.013DOI Listing
August 2018

Olaparib for the treatment of breast cancer.

Expert Rev Anticancer Ther 2018 06 30;18(6):519-530. Epub 2018 Mar 30.

a Department of Surgery, Oncology and Gastroenterology , University of Padova , Padova , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1458613DOI Listing
June 2018

Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients.

Nucl Med Commun 2017 Jun;38(6):537-545

aNuclear Medicine and Molecular Imaging Unit bBreast Surgery Unit cOncology 2 Unit, Veneto Institute of Oncology IOV - IRCCS dDepartment of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000671DOI Listing
June 2017

18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.

Curr Radiopharm 2016 ;9(3):244-257

Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV IRCCS, Padua, Italy.]> Maria Vittoria Dieci

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874471009666161019144950DOI Listing
August 2017

The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

Cancer Treat Rev 2016 May 28;46:9-19. Epub 2016 Mar 28.

Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.03.011DOI Listing
May 2016

Tumor Stroma Manipulation By MSC.

Curr Drug Targets 2016 ;17(10):1111-26

Laboratory of Cellular Therapy Department of Medical and Surgical Sciences for Children & Adults University-Hospital of Modena and Reggio Emilia Via del Pozzo 71, 41124 Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450117666160307143226DOI Listing
August 2017

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Oncologist 2015 Sep 5;20(9):1001-10. Epub 2015 Aug 5.

Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy; Division of Oncology, University Hospital, Ferrara, Italy; Division of Pathology, Modena University Hospital, Modena, Italy; Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy; Unità Operativa Multidisciplinare di Patologia Mammaria, Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy; Division of Medical Oncology, Ramazzini Hospital, Carpi, Italy; Department of Medical Oncology, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy; Division of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; Division of Medical Oncology, University Hospital, Parma, Italy; GlaxoSmithKline, Collegeville, Pennsylvania, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571802PMC
September 2015

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Eur J Nucl Med Mol Imaging 2015 Oct 31;42(11):1648-1655. Epub 2015 May 31.

Medical Oncology 2 Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-015-3088-4DOI Listing
October 2015

Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.

Ann Surg Oncol 2015 Sep 9;22(9):2881-7. Epub 2015 Jan 9.

Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padua, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-015-4371-0DOI Listing
September 2015

Blurring of boundaries in the doctor-patient relationship.

Lancet Oncol 2014 Dec 24;15(13):1423-1424. Epub 2014 Nov 24.

Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Brighton BN1 9RX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71122-2DOI Listing
December 2014

Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.

Stem Cells 2015 Mar;33(3):859-69

Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.1903DOI Listing
March 2015

Detection of microparticles from human red blood cells by multiparametric flow cytometry.

Blood Transfus 2015 Apr 23;13(2):274-80. Epub 2014 Oct 23.

Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2014.0136-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385076PMC
April 2015

Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact.

Anticancer Res 2014 Jul;34(7):3657-62

Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy Division of Medical Oncology 2, Venetian Oncology Institution IRCCS, Padova, Italy.

View Article

Download full-text PDF

Source
July 2014

Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Oncologist 2014 Aug 26;19(8):805-13. Epub 2014 Jun 26.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; and Istituto Oncologico Veneto IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Padova, Italy; Department of Pathology, University Hospital of Padova, Padova, Italy; Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/content/19/8/805.full
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122475PMC
August 2014

Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.

Expert Rev Anticancer Ther 2014 Sep 23;14(9):1041-50. Epub 2014 Jun 23.

Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35128, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.922415DOI Listing
September 2014

Trastuzumab-containing regimens for metastatic breast cancer.

Cochrane Database Syst Rev 2014 Jun 12(6):CD006242. Epub 2014 Jun 12.

Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD006242.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464904PMC
June 2014

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

J Clin Oncol 2014 Apr 3;32(10):1050-7. Epub 2014 Mar 3.

Valentina Guarneri and PierFranco Conte, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Padova, Padova; Daniele Giulio Generali and Alberto Bottini, U.O. Multidisciplinare di Patologia Mammaria, Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona; Antonio Frassoldati, University Hospital, Ferrara; Fabrizio Artioli and Katia Cagossi, Ramazzini Hospital, Carpi; Corrado Boni and Giancarlo Bisagni, Azienda Ospedaliera Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia; Luigi Cavanna, Hospital of Piacenza, Piacenza; Enrico Tagliafico, Enrica Roncaglia, and Simona Nuzzo, Center for Genome Research, University of Modena and Reggio Emilia; Antonino Maiorana, Federico Piacentini, Guido Ficarra, and Stefania Bettelli, Modena University Hospital, Modena, Italy; Ramona Swaby and Catherine Ellis, GlaxoSmithKline, Upper Providence, PA; and Clare Holford, GlaxoSmithKline, Stockley Park, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.4737DOI Listing
April 2014

Relapsed triple-negative breast cancer: challenges and treatment strategies.

Drugs 2013 Aug;73(12):1257-65

Medical Oncology 2, Istituto Oncologico Veneto IRCCS, University of Padova, Via Gattamelata 64, 35128 Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0091-6DOI Listing
August 2013

The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer.

Clin Breast Cancer 2012 Jun;12(3):157-66

Department of Oncology, Hematology, and Respiratory Diseases, University of Modena, Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.03.005DOI Listing
June 2012

Trastuzumab containing regimens for early breast cancer.

Cochrane Database Syst Rev 2012 Apr 18(4):CD006243. Epub 2012 Apr 18.

Department of Public Health, Microbiology and Virology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD006243.pub2
Publisher Site
http://dx.doi.org/10.1002/14651858.CD006243.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210PMC
April 2012

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

Expert Opin Pharmacother 2012 Feb 21;13(3):395-406. Epub 2012 Jan 21.

University of Modena and Reggio Emilia, University Hospital, Department of Oncology, Hematology and Respiratory Diseases , Via del Pozzo 71, Modena 41100 , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2012.651127DOI Listing
February 2012

Biomarkers predicting clinical benefit: fact or fiction?

J Natl Cancer Inst Monogr 2011 ;2011(43):63-6

Department of Oncology, Hematology and Respiratory Diseases, University Hospital, University of Modena and Reggio Emilia, Modena 41100, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgr021DOI Listing
March 2012

Bevacizumab treatment for advanced breast cancer.

Oncologist 2011 5;16(12):1684-97. Epub 2011 Oct 5.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-3721, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-0113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248767PMC
April 2012

Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications.

Lung Cancer 2011 Oct 20;74(1):145-8. Epub 2011 Jul 20.

Department of Oncology, Haematology and Respiratory Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena & University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.06.008DOI Listing
October 2011

Timing for starting second-line therapy in recurrent ovarian cancer.

Expert Rev Anticancer Ther 2011 Jan;11(1):49-55

Department of Oncology, Hematology and Respiratory Diseases, University Hospital, via del Pozzo 71, 41100 Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.204DOI Listing
January 2011

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Breast Cancer Res Treat 2010 Jul 2;122(1):181-8. Epub 2010 Apr 2.

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, University Hospital, Via del Pozzo 71, 41100 Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-0866-3DOI Listing
July 2010

Achievements and unmet needs in the management of advanced ovarian cancer.

Gynecol Oncol 2010 May 6;117(2):152-8. Epub 2010 Jan 6.

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena University Hospital, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.11.033DOI Listing
May 2010

Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

Expert Rev Anticancer Ther 2009 Nov;9(11):1549-57

Department of Oncology Hematology and Respiratory Diseases, University of Modena and Reggio Emilia University Hospital, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.124DOI Listing
November 2009

The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.

Cancer Biol Ther 2009 Aug 5;8(15):1456-8. Epub 2009 Aug 5.

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.8.15.9186DOI Listing
August 2009

Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.

Oncologist 2009 Jul 16;14(7):645-56. Epub 2009 Jul 16.

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, University Hospital, 41100 Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2009-0078DOI Listing
July 2009

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

Clin Breast Cancer 2008 Apr;8(2):192-4

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.n.022DOI Listing
April 2008

Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).

Clin Breast Cancer 2008 Feb;8(1):97-100

Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.n.010DOI Listing
February 2008